On Wednesday, Metsera reached an important technical milestone, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an upgrade to 92, up from 84 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating at the beginning of a new price run.
Metsera is not currently offering a proper buying opportunity. See if the stock goes on to form a sound pattern that could kick off a new price move.
Metsera showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
Metsera earns the No. 177 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
